Loading…
FitRx, LLC was cited by the Center for Drug Evaluation and Research for misbranding compounded semaglutide and tirzepatide products sold through its website in violation of sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company falsely represented itself as the compounder of these drug products when it was not, and made misleading claims suggesting the compounded drugs were FDA-approved or evaluated for safety and effectiveness by drawing comparisons to FDA-approved brand-name medications like Wegovy, Zepbound, Ozempic, and Mounjaro. These false and misleading representations on the company's website resulted in misbranded drugs being introduced into interstate commerce.